Table 1 Baseline characteristics of the study population

Age (years)

61.9 ± 12.5

65.1 ± 11.9

54.0 ± 10.4

Gender [male/female (male %)]

49/38 (56.3)

37/25 (59.7)

12/13 (48.0)

Duration of dialysis (years)

5.81 ± 5.90

6.38 ± 6.56

4.42 ± 3.51

Cause of ESRD (DM %)

40 (46.0)

30 (48.4)

10 (40.0)

 Hemoglobin (g/dL)

10.0 ± 0.80

10.1 ± 0.67

9.9 ± 1.05

 Transferrin saturation (%)

19.1 ± 8.86

17.7 ± 8.34

22.5 ± 9.34

 Serum ferritin (ng/dL)

52.1 ± 43.3

45.3 ± 28.1

69.1 ± 63.0

 Serum phosphate (mg/dL)

6.13 ± 1.15

6.21 ± 1.19

5.92 ± 1.07

 Corrected serum calcium (mg/dL)

9.24 ± 0.79

9.16 ± 0.77

9.45 ± 0.82

 Intact PTH (pg/dL)

261.1 ± 204.7

228.6 ± 146.3

341.9 ± 293.6

 Albumin (g/dL)

3.65 ± 0.38

3.72 ± 0.34

3.48 ± 0.44

 C-reactive protein (mg/dL)

0.30 ± 0.40

0.32 ± 0.38

0.27 ± 0.43

 Average DA dosage (μg/week)

34.4 ± 24.8

35.1 ± 27.1

32.5 ± 18.1

  ^aIV or oral iron preparations, N (%)

34 (39.1)

25 (40.3)

9 (36.0)

 Calcium carbonate, N (%)

53 (60.9)

42 (67.7)

11 (44.0)

 Sevelamer hydrochloride, N (%)

8 (9.2)

3 (4.8)

5 (20.0)

 Lanthanum carbonate, N (%)

37 (42.5)

27 (43.5)

10 (40.0)

 Cinacalcet, N (%)

20 (23.0)

14 (22.6)

6 (24.0)